1. 平台化是大趋势：Aidoc从"一个AI识别一种病"的单品模式，演进到"一个基础模型覆盖数十种急症"的平台模式。国内联影智能（累计20张三类证）、数坤科技（19张三类证）等知名企业也在走类似路径。如何在单一框架内实现多病种、多模态覆盖，是下一阶段竞争关键。

2. AI报告撰写即将成为主战场：First Read的出现标志着AI从"辅助诊断"迈向"辅助撰写"。美国放射科报告周转时间翻倍、人力短缺严重，中国市场同样面临影像科医生不足的挑战。但生成式AI的"幻觉"问题（测试中头部模型幻觉率仍达51.7%）要求全流程保留医师终审权。

3. FDA正在为AI器械创建新分类：2026年6月，FDA新增"心血管机器学习通知软件"产品代码QXO（Class II，510(k)路径），表明监管机构正在为AI/ML器械建立独立分类体系。出海企业需密切关注FDA分类动态，及时调整注册策略。

4. 合规路径参考：Aidoc的策略是先拿单品510(k)（已有18项批准），再以突破性认定加速平台化审批。国内企业出海可参考这一"步步为营"的FDA合规策略：先单品验证技术实力，再申请突破性认定获取加速通道，最终实现平台级产品覆盖。

Powered by CARE™ – the first clinical-grade foundation model in healthcare with FDA cleared solutions, built to solve one of the most critical bottlenecks in health systems

Aidoc, the global leader in clinical AI, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's novel multi-triage solution that flags a wide array of life-threatening, time-sensitive medical conditions, all within a single workflow. Built on CARE™, the first clinical-grade foundation model in healthcare with FDA cleared solutions, and deployed through Aidoc's aiOS™ platform, the solution is designed to help care teams attend to high-risk cases faster and more consistently across the health system.

This is the first-ever designation for AI with such broad coverage of medical conditions under one solution. The FDA grants Breakthrough Device Designation to technologies that both significantly advance the diagnosis of severe diseases and represent an unmet clinical need. The designation is intended to accelerate access to life-saving innovations by expediting the review process. In this case, it enables parallel review of double-digit indications within a single submission, an important step toward bringing comprehensive, high-accuracy clinical AI to routine care while maintaining robust safety and effectiveness standards.

"With this designation and our ecosystem of specialized partners, we can deliver a broader set of solutions across many service lines. CARE's ability to detect, characterize, measure, and compare findings underpins both current and in-development applications from triage to report drafting," said Elad Walach, co-founder and CEO, Aidoc. "We are tackling this from multiple angles, developing innovations in parallel and, as each is FDA cleared, bringing it to market – delivering valuable, safe solutions while building toward the next milestone."

Emergency departments and inpatient units are stuck in a vicious cycle. Rising patient volumes and a worsening shortage of physicians and nurses strain capacity, reducing efficiency and slowing care. Radiology is central: escalating imaging demand pushes radiology departments to their limits, creating delays that cascade downstream. Wait times are rising – in 2024, over one in four admitted patients waited four or more hours for a bed, with many waiting beyond 24 hours – and quality suffers as care continues under pressure. Comprehensive AI-powered triage can help break this cycle by flagging urgent cases and streamlining workflows to restore flow across the ED.

Aidoc has already become an essential tool for improving efficiency and care quality across health systems worldwide. With the most FDA-cleared AI indications in its category, Aidoc has scaled its impact across numerous disease states, all designed to accelerate patient care and ensure consistent quality at scale. Historically, these advancements expanded one condition at a time. CARE shifts this by enabling broad, simultaneous coverage across many pathologies. Clearance for multi-use systems covering tens of pathologies is complex and unprecedented, prompting renewed attention to design, development, and validation frameworks.

"The technology creates an extraordinary opportunity to advance healthcare, but success depends on more than the AI itself. It's about how it integrates, what data it can access, how it interacts with users, and how change is managed – ultimately ensuring patients are treated faster and better," said Michael Braginsky, co-founder and CTO, Aidoc. "It's a massive lift, but by leveraging the expertise and infrastructure we've built over the years, we're turning this vision into reality."

How It Works: CARE™ (Clinical AI Reasoning Engine) is specifically designed for clinical use, and trained on an enormous amount of real-world multimodal data to safely expand across diseases and care settings. Along with aiOS™, Aidoc's enterprise platform, health systems can integrate AI into existing workflows, manage performance, and deploy both Aidoc and third-party AI models across various service lines.

What's Next: The Breakthrough milestone advances Aidoc's roadmap toward a comprehensive, integrated clinical AI package, with additional CARE-powered capabilities such as auto-creation of draft reports, already in development. Aidoc's momentum includes 18 FDA clearances, deployments across over 150 U.S. health systems and more than 1,600 hospitals worldwide, as well as collaborations with Nvidia and AWS, with over $150 million committed to CARE's development and deployment.